• Developed proficiency in development, optimization and execution of molecular and cellular assays to address key scientific questions regarding oncogene amplification and cancer cell function. • Established unbiased image analysis pipeline, enabling high-content and in-depth readout in image-based assays.• Profiled DNA replication and DNA damage repair signaling pathways across 20+ cell lines, including normal, adherent cancer, suspension cancer, and neurosphere GBM cells, uncovering replication stress and DNA damage phenotypes in ecDNA-amplified tumors. • Discovered rampant transcription and R-loop contributing to replication stress by loss-of function experiments and genome instability pathway analysis. • Screened over 20 therapeutic targets across 10+ cell lines using high/mid-throughput viability assays, identifying potential treatments for ecDNA-amplified tumors. • Validated target efficiency and mechanism by DNA damage repair and cell cycle checkpoint pathway studies.• Lead the collaboration within and across different teams and a biotech company, driving the successful development of combined therapies that overcame resistance to conventional treatments.• Presented data regularly at lab meetings and conferences, contributing to knowledge dissemination and collaboration.• Mentored two junior graduate students in experimental design and execution, fostering skill development and independent research capabilities.

• Constructed tetO knock-in cells with CRISPR, enabling live cell imaging of ecDNA throughout cell cycle and demonstrating random segregation of ecDNA for the first time.• Conducted mid-to-large throughput phenotypic screening, identifying three lead probes in EGFR-amplified GBM models.• Collaborated with a chemical research team to identify targets for lead probes through proteomics analysis and validated target specificity and functionality using loss-of-function screening and overexpression in cell-based phenotypic assays.